| HOME >> BIOLOGY >> TECHNOLOGY |
VANCOUVER, British Columbia, May 19 /PRNewswire/ -- MagSense Life Sciences Inc, a leading developer and manufacturer of magnetic separation technologies, announced it will be participating in the 7th International Conference on the Scientific and Clinical Applications of Magnetic Carriers, being held May 21-24, 2008 in Vancouver, BC, Canada.
This conference is devoted to the preparation, analysis, use and application of magnetic microsphere and nanoparticles in basic and clinical research. MagSense will share its insights on the application of superparamagnetic particle technologies in biological research, diagnostics and drug development.
"At this conference, we'll discuss how our unique particles make it possible to perform demanding separations from large-volume and high-viscosity solutions such as serum or whole blood where efficiency matters," said Hao Shang, principal scientist at MagSense. "This efficiency is essential to saving valuable time and money while delivering positive results."
MagSense designs, manufactures and markets magnetic separation technologies, such as superparamagnetic particles. The company enables researchers to attain high-purity biomolecules through the application of magnetic separation technologies. These are highly reliable, convenient, and cost-effective alternatives to more traditional bioseparation methods. About
MagSense Life Sciences
Headquartered in West Lafayette, IN., MagSense Life Sciences, Inc,
develops, manufactures, and markets magnetic separation technologies for
life sciences research and biochemical production. The enhanced magnetic
properties and uniformity of its superparamagnetic microparticles are
ideally suited for pharmaceutical, biotechnology, and diagnostics
companies, as well as research centers and laboratories of academic,
government, and private foundations in the global market. Superparamagnetic
microparticle applications include affinity separations (such as, the
'/>"/>
| SOURCE MagSense Life Sciences Inc Copyright©2008 PR Newswire. All rights reserved |